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Abstract
Background: There is increasing evidence suggesting that the Locus Coeruleus plays a role in pain-related anxiety. Indeed, 
we previously found that prolonged arthritis produces anxiety-like behavior in rats, along with enhanced expression of 
phosphorylated extracellular signal-regulated kinase 1/2 (a marker of plasticity) in the Locus Coeruleus. However, it is 
unknown how this effect correlates with the electrophysiological activity of Locus Coeruleus neurons or pain-related anxiety.
Methods: Using the complete Freund’s adjuvant model of monoarthritis in male Sprague-Dawley rats, we studied the 
behavioral attributes of pain and anxiety as well as Locus Coeruleus electrophysiology in vivo 1 (MA1W) and 4 weeks (MA4W) 
after disease induction.
Results: The manifestation of anxiety in MA4W was accompanied by dampened tonic Locus Coeruleus activity, which was 
coupled to an exacerbated evoked Locus Coeruleus response to noxious stimulation of the inflamed and healthy paw. When 
a mitogen-activating extracellular kinase inhibitor was administered to the contralateral Locus Coeruleus of MA4W, the 
phosphorylated extracellular signal-regulated kinase 1/2 levels in the Locus Coeruleus were restored and the exaggerated 
evoked response was blocked, reversing the anxiogenic-like behavior while pain hypersensitivity remained unaltered.
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Conclusion: As phosphorylated extracellular signal-regulated kinase 1/2 blockade in the Locus Coeruleus relieved anxiety 
and counteracted altered LC function, we propose that phosphorylated extracellular signal-regulated kinase 1/2 activation in 
the Locus Coeruleus plays a crucial role in pain-related anxiety.
Keywords: Locus Coeruleus, anxiety, pain, arthritis, ERK1/2.
Introduction
Pain is a disease with repercussions that reach far beyond 
hypersensitivity. For example, chronic pain is associated with 
an alarming risk of suffering emotional disturbances, such 
as those characterized by persistent anxiety, establishing a 
vicious circle that magnifies the painful experience (Price, 
2000; Sharp and Keefe, 2005; Edwards et al., 2011). In the case 
of painful arthritis, it is estimated that more than 30% of the 
arthritic population in the US suffers anxiety (Murphy et  al., 
2012). However, while this comorbidity is clinically well estab-
lished, the underlying mechanisms remain poorly studied. We 
previously reported that prolonged experimental arthritis pro-
duces anxiety-like behavior in rats (Borges et al., 2014), as also 
observed elsewhere (Narita et  al., 2006; Amorim et  al., 2014). 
This provides us with a reliable experimental tool to assess 
the mechanisms underlying the development of anxiety in 
association with arthritic pain. By studying phosphorylated 
isoforms of extracellular signal-regulated kinase 1/2 (pERK1/2) 
as a marker of plasticity, we found that long-term arthritis 
enhances pERK1/2 expression in the Locus Coeruleus (LC) and 
its projection area, the prefrontal cortex (Borges et  al., 2014), 
strongly suggesting that this pathway is implicated in the 
effects of arthritis.
The noradrenergic-LC system is a bilateral pontine nucleus 
that modulates pain perception through an intricate network of 
projections. It is widely known that acute noxious or inflamma-
tory stimuli activate LC descending innervations to the spinal 
cord to promote feedback inhibition of pain (Kwiat and Basbaum, 
1992; Ossipov et al., 2010; Kwon et al., 2013). However, in more 
complex pain conditions, where anxiety and other features also 
manifest, there is little information available regarding the reg-
ulation of the LC. This is particularly true from an electrophysi-
ological perspective and with regards to possible repercussions 
for its ascending projections to the prefrontal areas where the 
emotional consequences of chronic pain might be modulated 
(Berridge and Waterhouse, 2003; Sara, 2009) (Figure 1A). Indeed, 
it is known that LC function is compromised in stressful and 
anxiogenic conditions (Bravo et  al., 2013; George et  al., 2013; 
McCall et al., 2015) and that experimental arthritis engages a 
stress component involving the corticotropin-releasing factor 
(CRF) (Hummel et al., 2010; Borges et al., 2015). Therefore, it is 
possible that the LC may modulate the sensorial and affective 
features of chronic pain in different ways (Alba-Delgado et al., 
2013; Bravo et al., 2013; Borges et al., 2014).
The aim of the present work was to study the role and 
activity of LC neurons in pain-related anxiety. Furthermore, as 
ERK1/2 activity has been implicated in long-lasting plasticity in 
several areas involved in pain processing (e.g., the spinal cord 
and anterior cingulate cortex) (Ji et al., 2009; Zhong et al., 2012), 
we also set out to investigate the implication of the ERK1/2 cas-
cade on the electrophysiological activity of the LC in painful 
states. As such, we have used monoarthritis (MA) as a model of 
inflammatory pain, studying both the early (anxiety-free) and 
late (anxiety associated) phase of the disease. In this system, we 
evaluated the characteristics of LC discharge at baseline and fol-
lowing noxious stimulation, and we also studied the behavioral 
and electrophysiological effects of pharmacologically inhibiting 
ERK1/2 activation at the LC level.
Methods
Animals and Experimental Design
Adult male Harlan Sprague-Dawley rats (200–300  g, 2–4/cage: 
University of Cádiz ES110120000210) were housed under con-
trolled conditions: food and water supplied ad libitum; a 
12-hour-light/12-hour-dark cycle; constant temperature (22°C) 
and humidity (45–60%). All experiments were carried out in 
accordance with the European Communities Council Directive 
of September 22, 2010 (2010/63/EC), Spanish Law (RD 53/2013), 
and the ethical guidelines governing the investigation of experi-
mental pain in animals (Zimmermann, 1983). All the experi-
mental protocols were approved by The Animal Research Ethics 
Committee at the Faculty of Medicine of the University of Cadiz.
Behavior (Cohort 1)  and electrophysiological LC activity 
(Cohort 2) were evaluated in control rats, and in rats 1 (MA1W) 
or 4 weeks (MA4W) after inducing MA. The effect of intra-LC 
administration of SL327 on LC electrophysiological activity and 
behavior was evaluated in control and MA4W rats (Cohort 3 and 
4, respectively). In addition, immunohistochemistry was per-
formed on parallel groups (Cohort 5; Figure 1B).
MA Induction and Behavioral Assessment
MA was induced under isoflurane anesthesia (4% to induce anes-
thesia and 2% to maintain it: Abbott, Madrid, Spain) by injecting 
a complete Freund’s adjuvant solution (CFA, 50 µL) into the left 
Significance Statement
This work provides strong evidence of the prominence of the Locus Coeruleus (LC)-noradrenergic system in the development 
of anxiety in chronic pain, a widely known occurrence in clinical practice. We show that this phenomenon is accompanied by 
severe changes in the activity of the LC neurons. Indeed, we propose a molecular pathway that is crucial for the development of 
anxiety in such conditions, involving the activation of extracellular signal-regulated kinase 1/2 (pERK1/2). The manipulation of 
LC activity by blocking the overexpression of pERK1/2 produced a clear reversion of the anxiety behavior produced by prolonged 
exposure to a painful condition, without interfering with the pain threshold. This outcome supports the dissociation of the 
mechanisms underlying the sensorial-affective component of pain.
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tibiotarsal joint (ipsilateral) as described previously (Butler et al., 
1992; Borges et al., 2014). The CFA-injected rats were studied 1 
and 4 weeks after the induction of MA, and the animals that 
developed polyarthritis were excluded from the study. Control 
rats were injected with the vehicle solution and were studied 1 
or 4 weeks later in function of the experiment (Figure 1B).
The paw pressure test was used to evaluate secondary 
mechanical hypersensitivity (Randall and Selitto, 1957). Briefly, 
increasing pressure was gradually applied to the dorsal side of 
the paw using a graded motor-driven device (Ugo Basile, Varese, 
Italy), beginning at 30 g of pressure. A reduction in the pressure 
that provoked withdrawal indicates hyperalgesic-like hyper-
sensitivity. Two measurements were taken in both the ipsi- and 
contralateral paws.
Anxiety-like behavior was evaluated using the elevated zero 
maze (EZM; Borges et al., 2014), which consisted of a black cir-
cular platform divided into 4, equal-sized quadrants: 2 opposing 
open quadrants with 1-cm high clear borders to prevent falls; 
and 2 opposing closed quadrants with black walls. A 5-minute 
trial was carried out under the same lighting conditions, which 
began by placing the animal in the center of one of the closed 
quadrants. Spontaneous Motor Activity Recording and Tracking 
(Panlab S.L., Barcelona, Spain) software was used to analyze the 
time the rat spent in the open arms and the total distance each 
rat traveled. A  decrease in the time spent in the open area is 
related to anxiety-like behavior.
LC Electrophysiology
Details of the electrophysiological procedures can be found in 
the Supplementary Information. As the ascending pain pathway 
is mainly contralateral (Pertovaara, 2006), single-unit extracel-
lular recordings of LC neurons were obtained from the brain 
hemisphere contralateral to the site of injection (Berrocoso and 
Mico, 2007; Alba-Delgado et al., 2013) (Figure 1A). When a single 
LC unit was isolated, the spontaneous basal discharge (baseline) 
was recorded for 2 to 5 minutes, and the following parameters 
were calculated: firing rate (Hz), the incidence of burst activity, 
and the number of spikes per burst. A LC cell was considered 
to exhibit burst firing when it displayed at least 2 spikes with 
Figure 1. Summary of the methodological approach. (A) Proposed pathway involved in pain transmission from the paw, passing through the spinal cord (SC), the Locus 
Coeruleus (LC), and reaching the prefrontal cortex (PFC: ascending dashed lines) to trigger the descending LC projections to the SC (descending solid line). (B) Represen-
tation of the experimental design. (C) Representation of the recording electrode’s position. (D) Typical LC spike shape. (E) Pontamine spot certifying the correct position 
of the recording electrode. (F) Electrophysiological protocol used for mechanical stimulation of the paw. (G) Oscillography trace representing the evoked-response (ER) of 
paw compression (PC), duration (D) of the response, suppression period (SP) and postcompression tonic activity of a LC neuron. C, contralateral; CFA, complete Freund’s 
adjuvant; Contra, contralateral; IHC, immunohistochemistry; Ipsi, ipsilateral; S, stimulation; W, week.
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an initial interspike interval <80 milliseconds and with subse-
quent interspike intervals of at least 160 milliseconds (Grace 
and Bunney, 1984). The sensory-evoked response of LC neurons 
was studied after stable basal spontaneous firing by manually 
applying mechanical pressure for 1 second to the ipsilateral or 
contralateral paw (paw compression [PC]) using surgical for-
ceps (Figure 1E). This sensory-evoked discharge was followed 
by a suppression period (SP) (Grant and Weiss, 2001; West et al., 
2009; Bravo et al., 2013; Torres-Sanchez et al., 2013), although 
importantly, repeated trials using this type of PC produces nei-
ther sensitization nor habituation in naive animals (West et al., 
2010). For each neuron recorded, PC was applied 5 times with a 
100-second interval, quantifying the sensory evoked-response, 
the duration of the response, and the SP after PC. Finally, a simi-
lar PC was applied to the contralateral paw (Figure 1F). To pre-
vent paw damage, no more than 4 neurons were studied per rat. 
The postcompression tonic activity was measured over an inter-
val of 70 seconds, starting 30 seconds after each PC. Changes in 
the postcompression discharge were expressed relative to the 
baseline for each neuron and averaged across recordings. At the 
end of the experiment, a Pontamine Sky Blue mark was depos-
ited by applying a 5-μA cathodic current through the recording 
electrode and subsequently, the site of recording was verified 
histologically (Figure 1G). Only measurements from cells within 
the LC area were included in this study.
For the electrophysiological experiments to assess the effect 
of SL327, a mitogen-activating extracellular kinase (MEK) inhibi-
tor that has a negative impact on ERK1/2 phosphorylation (S4069: 
Sigma-Aldrich, Madrid, Spain) was used in another set of rats. In 
these experiments, a calibrated pipette was glued adjacent to a 
recording micropipette (Ruiz-Ortega and Ugedo, 1997), and it con-
tained SL327 dissolved in the vehicle solution of 50% DMSO and 
50% of Dulbecco’s buffered saline containing: NaCl, 136.9  mM; 
KCl, 2.7 mM; NaH2PO4, 8.1 mM; KH2PO4, 1.5 mM; MgCl2, 0.5 mM; 
and CaCl2, 0.9 (pH 7.40). Pressure pulses (50–150 milliseconds) 
were applied with a Picospritzer II (General Valve Corporation, 
Fairfield, NJ) to inject the compound. The volume injected was 
measured by monitoring the movement of the meniscus in the 
pipette, having previously calibrated the device to deliver 2 nL 
of the solution with each pulse. This procedure was performed 
during the recording of the neuron. Injecting the vehicle solution 
alone did not affect LC electrical activity in control or MA rats.
Intra-LC Drug Administration
Five days before completing the 4 weeks of MA, rats were anaes-
thetized with an i.p. injection of ketamine (100 mg/kg) and xyla-
zine (20 mg/kg), and they were placed in a stereotaxic frame with 
their head tilted at an angle of 15º to the horizontal plane (nose 
down). A guide cannula (22 gauge, 15-mm length) was implanted 
in the contralateral (right side) LC at the same coordinates rela-
tive to lambda as those used in the electrophysiological studies 
(Paxinos and Watson, 2009). After positioning, the guide cannula 
was fixed to the skull and anchored to stainless screws with 
polyacrylic cement. Microinjection was performed by lowering 
into the brain a removable injector 1 mm longer than the guide 
tip, which was connected to a 10-μL Hamilton syringe (Bravo 
et al., 2013). Animals received a 0.5-µL injection administering 
4.17 mM of SL327 in DMSO as the vehicle. The behavioral tests 
(paw pressure and EZM tests) were performed within 10 to 25 
minutes of drug administration. Random animals from each 
group were selected for histological confirmation of the locali-
zation of the implanted cannula, and any animal in which it was 
misplaced was excluded.
Immunohistochemistry
Control, MA1W, and MA4W rats were anaesthetized with 8% 
chloral hydrate (400  mg/kg), and they were immediately per-
fused through the ascending aorta with 250 mL of oxygenated 
Tyrode’s solution followed by 750 mL of 4% paraformaldehyde 
in phosphate buffer (0.1 M, pH 7.2). The rat’s brain was removed 
and processed for free-floating immunohistochemistry as 
described previously (Nascimento et al., 2011; Borges et al., 2013). 
Transverse sections of the LC region were washed, blocked (Cruz 
et al., 2005), and then incubated with antibodies against tyrosine 
hydroxylase (TH, raised in sheep, 1:2000; 48 hours, Abcam), the 
phosphorylated ERK1/2 isoforms (raised in rabbit, pERK1/2, 1:500, 
48 hours; Acris Antibodies, Herford, Germany), or both to con-
firm the nature and localization of pERK1/2 positive cells in the 
LC, as described elsewhere (Borges et al., 2013). Antibody binding 
to pERK1/2 was detected with a biotinylated donkey anti-rabbit 
secondary antibody (1:200, 1 hour; Jackson Immunoresearch 
Laboratories), and it was visualized with an ABC kit (1:200, 1 
hour; ABC Elite kit, Vector Laboratories, Peterborough, UK) and a 
3,3’-diaminobenzidine solution (10 minutes). In the case of TH, 
an alexa 568 conjugated donkey anti-sheep antibody was used 
(1:1000, 1 hour; Invitrogen, Life Technologies S.A., Madrid, Spain). 
For dual pERK1/2 and TH visualization, the secondary antibod-
ies used were a biotinylated donkey anti-rabbit (1:200, 1 hour) 
followed by incubation with Streptavidin conjugated alexa 488 
(1:200, 2 hours; Invitrogen), and an alexa 568 conjugated donkey 
anti-sheep antibody (1:500, 2 hours).
TH positive cells were quantified by counting the number of 
labeled cell bodies per animal in at least 6 sections containing 
the LC region (caudal or the rostral portions) under an Olympus 
BX60 microscope coupled to a digital camera (Olympus DP71) 
and image software (Cell F 2.4). The average number of immuno-
reactive (IR) cells/section/side was used for statistical purposes. 
The expression of pERK1/2 in the LC was quantified by densi-
tometry, as described previously (Borges et al., 2013).
Western Blotting
Detailed information can be found in the supplementary 
Information.
Statistical Analysis
All the data are presented as the means ± SEM, and the 
results were all analyzed using STATISTICA 10.0 (StatSoft) or 
GraphPad Prism 5 software (GraphPad Software), applying 
either a Student’s t test (unpaired or paired, 2-tailed), or a 1-way 
or 2-way ANOVA, followed by the appropriate posthoc tests 
(Bonferroni or Dunnett’s tests). The independent variables were 
MA (between groups), paw, or drug treatment (between groups) 
(supplementary Table 1). A Fisher’s exact test was used to evalu-
ate the incidence of burst activity. Significance was accepted at 
P < .05.
Results
Nociceptive and Anxiety-Like Behavior
The paw withdrawal threshold was evaluated in the ipsilateral 
(inflamed) paw of MA rats, and it was significantly lower than 
that of control rats (P < .001 for MA1W and MA4W), indicative 
of mechanical hypersensitivity (Figure 2A). By contrast, no dif-
ferences were observed when the withdrawal threshold was 
evaluated in the contralateral paw. In addition, MA4W rats spent 
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significantly less time in the open arms of the EZM than control 
rats, indicative of anxiety-like behavior (P < .001), although no 
such changes were observed in MA1W rats (Figure 2B). Notably, 
no significant changes were observed in the total distance 
traveled in the EZM, indicating that locomotor activity was not 
impaired in the MA rats (Figure 2C).
Spontaneous Activity of Contralateral LC Neurons
Data from 57, 36, and 37 neurons were recorded from 19 control, 
11 MA1W, and 17 MA4W rats, respectively, and to maintain the 
same experimental and recording conditions, whenever possi-
ble at least one control and one MA rat (MA1W or MA4W) were 
evaluated on the same day. The basal spontaneous LC activity 
was significantly lower in MA4W rats than in the controls (P < .01: 
Figure 2D), although no significant differences were observed 
when the MA1W rats were compared with the controls. While 
the burst activity tended to be weaker in the MA1W and MA4W 
rats (P = .059 and P = .056 vs control, respectively: Figure 2E), the 
number of spikes per burst did not differ among the 3 experi-
mental groups (Figure 2F).
Activity of LC Neurons Evoked by Ipsilateral PC
When the electrophysiological profile of the sensory-evoked 
response was assessed during ipsilateral PC (Figure 1F-G), the 
basal firing rate in each experimental group followed the same 
pattern as that described in Figure 2D (data not shown). The 
application of 5 sequential stimulations did not significantly 
alter any parameters of the sensory responses studied, irrespec-
tive of the treatment (S1 vs S5 for control, MA1W and MA4W, 
P > .05). However, the activity evoked by the last stimulation in 
MA4W rats was significantly stronger than that in the control 
and MA1W rats (P < .05 vs control) (Figure 3A). This reinforce-
ment was particularly evident when the averaged data of all 5 
stimulations was analyzed, reflecting the significant increase in 
this parameter in MA4W rats (P < .001 vs control) (Figure 3A, right 
bar graph). Indeed, this analysis also revealed a significantly 
weaker evoked response in MA1W rats than in the control rats 
(P < .05) (Figure 3A, right bar graph). Furthermore, the response 
also lasted longer in MA4W, particularly following stimula-
tions S3 (P < .01), S4 (P < .05), and S5 (P < .001 vs control) (Figure 
3B). Likewise, a significant increase in duration was observed in 
Figure 2. Nociception, anxiety, and basal/spontaneous electrophysiological Locus Coeruleus (LC) properties in control and 1- and 4-week MA rats (MA1W and MA4W). 
(A) Mechanical hypersensitivity was confirmed by a lower withdrawal threshold of the ipsilateral paw of MA rats: 2-way ANOVA and Bonferroni posthoc, control vs 
MA1W/MA4W for each paw (n = 6). (B) The anxiety-like behavior was reflected by a significant decrease in the time spent in the open arms of the elevated zero maze 
(EZM): 1-way ANOVA and Dunnett’s posthoc, control vs MA4W (n = 6/7). (C) The total distance traveled in the EZM was unaffected: 1-way ANOVA and Dunnett’s posthoc 
(n = 6/7). (D) The spontaneous firing discharge of LC neurons diminished significantly in MA4W rats: 1-way ANOVA and Dunnett’s posthoc, control vs MA4W. (E) The 
incidence of spontaneous burst activity in MA rats tended to decrease: Fisher’s exact test. (F) The number of spikes/burst was maintained. AU, arbitrary units. **P < .01 
and *** P < .001.
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MA4W rats when the averaged data of all stimulations was com-
pared with the responses of the control (P < .001) (Figure 3B, right 
bar graph). No significant differences were observed regarding 
the duration of the evoked response in MA1W rats, and no sig-
nificant differences were observed in the suppression period 
between each of the experimental groups (Figure 3C).
We also explored the tonic LC rate after each noxious stimu-
lus, expressed relative to the basal firing rate (postcompression 
tonic activity) (Figure 1E). In the control group, a mild decrease 
(12.2%) in tonic activity was observed during the application of 
mechanical stimulation, while the MA1W rats hardly changed 
their spontaneous firing pattern in response to sequential stim-
ulation. By contrast, sequential PCs in MA4W rats induced an 
increase in tonic activity of approximately 16.5%, significantly 
higher than in the MA4W and control rats following each PC 
(P < .05 for S2; P < .01 for S1 and S5; P < .001 for S3 and S4) (Figure 
3D). Moreover, there was a significant increase in the averaged 
postcompression tonic activity in MA1W and MA4W rats com-
pared with the control (P < .05 and P < .001, respectively) (Figure 
3D, bar graph on the right). The LC response following PC applied 
Figure 3. Effect of sequential ipsilateral paw compressions (PCs) on the electrophysiological response of Locus Coeruleus (LC) neurons in control and 1- and 4-week 
MA rats (MA1W and MA4W). (A-D) Graphs depicting the effect of sequential ipsilateral PC on the phasic activity of LC neurons (n = 10, 8 and 11 neurons in control, 
MA1W and MA4W, respectively) and the overall data for all stimulations. (A) The evoked-response decreased in MA1W and increased in MA4W rats: 1-way ANOVA and 
Dunnett’s posthoc, MA1W/MA4W vs control. (B) The duration of the response increased in MA4W rats: 1-way ANOVA and Dunnett’s posthoc, MA4W vs control. (C) The 
SP did not change: 1-way ANOVA and Dunnett’s posthoc. (D) The postcompression tonic activity was altered in MA1W and MA4W rats: 1-way ANOVA and Dunnett’s 
posthoc, MA1W/MA4W vs control. (E-G) Oscillography traces representing the LC responses to ipsilateral stimulation S1 (E), S3 (F), and S5 (G) in control, MA1W, and 
MA4W rats. FR, firing rate; S, stimulation. *P < .05, **P < .01, and ***P < .001.
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to the ipsilateral paw in control, MA1W, and MA4W rats to S1 
(Figure 3E), S3 (Figure 3F), and S5 (Figure 3G) is also shown in 
representative histograms.
Activity of LC Neurons Evoked by Contralateral PC
After 5 successive ipsilateral PCs, one compression was applied 
to the noninflamed contralateral paw (Figure 1F), which failed 
to evoke a response from the LC neurons of control rats (Figure 
4A). However, when the same procedure was applied to monoar-
thritic rats after 1 or 4 weeks of inflammation, a sensory-evoked 
response was observed that was particularly evident in MA4W 
rats (Figure 4A). Indeed, burst activity appeared to be stronger 
in MA1W rats than in control rats (P = .052), and in MA4W rats it 
was significantly higher than in the control (P < .05) (Figure 4A). 
No significant differences were detected between the MA1W and 
MA4W rats (see representative histograms of the LC response 
to PC applied to the contralateral paw in control, MA1W, and 
MA4W rats) (Figure 4B).
TH and pERK1/2 Expression in the LC
Since increased use of noradrenaline is accompanied by upreg-
ulation of TH, the rate-limiting enzyme for noradrenaline syn-
thesis (Smith et al., 1991), we assessed TH expression in the LC. 
As expected, TH was detected in the cytoplasm and dendrites 
of noradrenergic neurons. Moreover, at the caudal level of the 
LC there were significantly more neurons expressing TH in 
MA4W rats than in control animals (P < .01 and P < .05 for the 
ipsi- and contralateral sides, respectively) (Figure 5A,C). Similar 
results were obtained when considering the entire rostro-caudal 
extension (total portion, P < .05 for ipsi- and contralateral sides), 
although no differences were observed in the rostral domain of 
MA4W rats or when comparing the ipsi- and contralateral sides 
(Figure 5A). TH labeling may be so dense that it may become 
difficult to count the number of TH IR cells (Figure 5C), although 
this problem can be overcome by also determining the amount 
of TH in the LC in western blots, which confirmed the increased 
TH expression in the LC of MA4W animals (Figure 5D,Da).
Similar results were obtained when pERK1/2 was evaluated 
in the LC, which was detected in the cytoplasm, nucleus, and 
dendrites of neurons, as well as in a large number of fibers sur-
rounding the LC neurons (Borges et al., 2013). Again, no differ-
ences were observed between the ipsi- and contralateral LC. The 
density of pERK1/2 labeling in MA4W rats increased significantly 
in the caudal and rostral domain of the LC compared with con-
trol rats (ipsilateral, P < .001 caudal or P < .01 rostral; contralateral, 
P < .001: Figure 5B,E) as well as along the entire rostro-caudal 
extension (ipsilateral, P < .001; contralateral, P < .001) (Figure 
5B). These data suggest that prolonged inflammatory pain pro-
duces stronger activation of the ERK cascade in the LC (MA4W). 
Moreover, a slight increase in pERK1/2 expression was detected 
in the contralateral LC of MA1W rats when the entire rostro-
caudal extension was considered (P < .05) (Figure 5B). It appears 
that most of the pERK1/2 is found in noradrenergic neurons in 
the LC (Figure 5F).
Effect of Intra-LC SL327 Microinjection on the 
pERK1/2 Expression
To find an appropriate concentration of SL327 to use in the 
behavioral and electrophysiological experiments (the MEK 
inhibitor that affects ERK1/2 phosphorylation; Papadeas et al., 
2008), 2 doses were evaluated based on the literature: 4.17 mM 
and 8.35  mM. In a pilot study to evaluate the inhibition of 
pERK1/2 in MA4W upon microinjection of SL327, both 4.17 mM 
and 8.35 mM produced appropriate inhibition when the accu-
mulation of pERK1/2 was assessed in MA4W rats that received 
SL327 or the vehicle solution alone (P < .001) (Figure 6A). Thus, 
the lower dose of 4.17 mM was used in all the following studies.
Electrophysiological Effect of Intra-LC SL327 
Microinjection
As the group of MA4W rats presented the more prominent 
changes in spontaneous LC activity and pERK1/2 accumulation, 
the effect of SL327 on the LC discharge evoked by ipsilateral PC 
was studied in control and MA4W rats. After noxious stimula-
tions S1, S2, S3, and S4, a dose of SL327 (8.35–33.39 pmol) was 
administered to the LC and the evoked response was measured 
(Figure 6B). SL327 administration did not significantly modify 
the responses provoked by the stimulation of the LC in control 
animals (evoked response, duration, suppression period, and 
postcompression tonic activity: S1 vs S2-S5, P > .05: Figure 6C-F), 
yet SL327 produced a dose-dependent decrease in the evoked 
discharge after each noxious stimulus in MA4W rats, as was par-
ticularly evident at S5 (S1 vs S2-S4, P > .05; S1 vs S5, P < .01) (Figure 
6C). Moreover, we found that the discharge evoked in MA4W and 
control rats receiving SL327 differed significantly after S4 and S5 
(control vs MA4W for S4 and S5, P < .05 and P < .01, respectively). 
However, the duration of the response in control and MA4W rats 
was not modified by microinjection of SL327 (P > .05). Overall, 
these results suggested that SL327 decreased the duration of 
the response that had been significantly increased in MA4W 
rats (Figure 3B). In MA4W rats, SL327 induced a dose-depend-
ent increase in the period of suppression that was statistically 
different from the basal S1 value following the administration 
of 33.39 pmol of SL327 (MA4W: S1 vs S5, P < .01) (Figure 6E) as 
well as compared with the response in control animals receiv-
ing the same dose (control vs MA4W, P < .001) (Figure 6E). Finally, 
microinjection of SL327 produced a significant decrease in the 
postcompression tonic activity in MA4W animals relative to the 
basal S1 value (S1 vs S3-S5, P < .001) (Figure 6F) and to the control 
animals receiving the same dose (control vs MA4W, P < .05 for S3, 
Figure 4. Effect of contralateral stimulation on the incidence of evoked burst activity in control and 1- and 4-week MA rats (MA1W and MA4W). (A) In MAW rats, there 
is an increase in the incidence of evoked burst activity: *P < .05 (Fisher’s exact test). (B) Representation of the oscillography traces for the Locus Coeruleus (LC) response 
to contralateral stimulation.
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Figure 5. Phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2) and tyrosine hydroxylase (TH) levels in the Locus Coeruleus (LC) of control and 1- and 
4-week MA rats (MA1W and MA4W). (A) There were significantly more TH immunoreactive (IR) cells in the caudal and total LC of MA4W rats: 2-way ANOVA and Bonfer-
roni posthoc, control vs MA4W for each side (n = 5–7). (B) The pERK1/2 mean gray values were significantly higher in the entire rostro-caudal extension of the LC: 2-way 
ANOVA and Bonferroni posthoc control vs MA1W/MA4W for each side (n = 5–7). (C) Representative photomicrographs showing TH and detailing the immunolabeling in 
the amplified inset. Scale bar = 100 µm. (D) The increase in TH expression in MA4W rats was also observed in western blots. (Da) Representative regions of the immuno-
blots showing the bands for TH and Tubulin proteins. (E) Representative photomicrographs showing pERK1/2 in the caudal and rostral domains. Scale bar = 100 µm. (F) 
Photomicrographs showing the pERK1/2 immunolabeling in TH positive neurons in the LC. Scale bar = 50 µm. AU, arbitrary units; C, contralateral; I, ipsilateral. *P < .05, 
** P < .01, and ***P < .001.
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Figure 6. Effect of microinjecting the MEK inhibitor SL327 into the Locus Coeruleus (LC) on the electrophysiological parameters in control and 4-week MA rats (MA4W). 
(A) Expression of phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2; 42–44 kDa) in the LC in response to SL327 microinjection (4.17 mM and 8.35 mM) 
and the corresponding images of western blots (relevant regions of the original blot presented below the graph): 1-way ANOVA and Dunnett’s posthoc, control, or MA + 
SL327 vs MA4W + DMSO (n = 4 assays). (B) Electrophysiological protocol used to study the effects of SL327 in the LC response to mechanical stimulation of the paw. (C) 
The sensory-evoked response of MA4W rats was significantly weaker: repeated measures and Bonferroni posthoc test comparing control vs MA4W; 1-way ANOVA and 
Dunnett’s posthoc test comparing S2-S5 vs S1 (n = 6–8 neurons/experimental group). (D) No significant effects were observed on the duration of the response. (E) The 
SP of MA4W rats increased significantly following SL327 microinjection: repeated measures and Bonferroni posthoc test comparing control vs MA4W; 1-way ANOVA 
and Dunnett’s posthoc test comparing S2-S5 vs S1 (n = 6–8 neurons/experimental group). (F) SL327 microinjection significantly dampened the change in tonic activity 
relative to the basal values in MA4W rats: 1-way ANOVA and Dunnett’s posthoc test comparing S2-S5 vs S1; repeated measures and Bonferroni posthoc test compar-
ing control vs MA4W (n = 6–8 neurons/experimental group). (G) Representative oscillography traces for S1, S3, and S5 in control and MA4W rats: *P < .05, **P < .01, and 
***P < .001 (repeated measures); ++P < .01 and +++P < .001 (1-way ANOVA).
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S4, and S5) (Figure 6F). Representative histograms were drawn 
up of the LC response in control and MA4W rats to S1, S3, and 
S5 PC applied to the ipsilateral paw in the presence of SL327 
(Figure 6G).
Effect of Intra-LC SL327 Microinjection on 
Nociception and Anxiety
Having verified that SL327 (4.17 mM) reversed the accumulation 
of pERK1/2 in the LC to control levels (Figure 6A), we assessed 
the behavioral effects of this MEK inhibitor after micro-injec-
tion into the LC  (Figure 7A). A significant decrease in the pain 
threshold was observed in the ipsilateral paw of MA4W rats 
before contralateral microinjection of SL327 (predrug, P < .05 
vs contralateral paw), which persisted after administering the 
inhibitor (SL327, P < .01 vs contralateral paw) (Figure 7B). Hence, 
pERK1/2 inhibition appeared to have no effect on the ipsilat-
eral and contralateral paw withdrawal threshold in MA4W rats. 
However, when their anxiety-like behavior was assessed, micro-
injection of SL327 reverted the shorter times spent by MA4W 
rats in the open arms that were indicative of an anxiolytic-like 
effect (P < .05, MA4W saline vs MA4W SL327) (Figure 7C). No 
changes were observed in control animals receiving SL327 and 
moreover, no significant changes were observed in the total dis-
tance traveled (Figure 7D).
Discussion
The present study provides new evidence and further confirma-
tion of the role played by ERK1/2 signaling in the contralateral/
ascending pathway of the LC, a crucial element in the manifes-
tation of anxiety associated with MA pain. Indeed, in addition 
to our previous reports of enhanced ERK1/2 signaling activity in 
the LC associated with prolonged MA (Borges et al., 2014, 2015), 
we explored here the electrophysiological activity of the LC neu-
rons in such painful conditions, also evaluating their tonic and 
phasic activities. After finding that when MA provokes anxiety 
it is accompanied by low tonic and high phasic activity of LC 
neurons, we pharmacologically blocked the activation/phospho-
rylation of ERK1/2 on the side contralateral to the inflamed joint, 
assessing the impact on LC electrophysiology and behavior. Such 
manipulation reversed the electrophysiological parameters and 
anxiety-like behavior, without interfering with the withdrawal 
threshold in MA4W rats.
In accordance with our previous data, we show that the 
withdrawal threshold in MA rats decreases significantly in the 
first week of inflammation, although these animals do not 
display emotional changes (Borges et  al., 2014). Hence, MA1W 
rats serve as a control for pain in the absence of emotional 
changes given that the anxiogenic phenotype was not evident 
until 4 weeks of MA. Electrophysiological studies highlighted 
the lower firing rate in the contralateral LC of MA4W rats and 
a tendency towards weaker burst activity in MA1W and MA4W 
rats. In addition, increases in TH expression were only evident 
in MA4W rats, suggesting an increase in the demand for this 
neurotransmitter. These data are consistent with the altered 
climbing behavior in the forced swimming test observed pre-
viously in MA4W rats (Borges et  al., 2014), possibly reflecting 
diminished noradrenaline availability in the face of a stressful 
situation (Detke et al., 1995; Cryan et al., 2005). Interestingly, we 
Figure 7. Effect of microinjecting the mitogen-activating extracellular kinase (MEK) inhibitor SL327 into the Locus Coeruleus (LC) on the nociceptive and anxiety 
behavior of control and 4-week MA rats (MA4W). (A) Histological representation of the unilateral injection sites and cannula placement within the LC. (B) SL327 micro-
injection into the LC had no effect on the paw withdrawal threshold: 2-way ANOVA and Bonferroni posthoc (n = 5). (C) SL327 microinjection into the LC reversed the 
anxiety-like behavior in MA4W rats, as reflected by the increase in the time spent in the open arms: 2-way ANOVA and Bonferroni posthoc (n = 6). (D) The locomotor 
activity in the elevated zero maze test was not affected by microinjection of SL327: *P < .05 and **P < .01.
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also reported an increase in TH expression 4 weeks after chronic 
constriction injury, a model of neuropathic pain caused by nerve 
trauma. No significant changes in the spontaneous firing rate 
were detected after nerve constriction, although an increase in 
burst activity was evident (Alba-Delgado et al., 2013). These dif-
ferences indicate that the origin of pain is decisive, suggesting 
that different and specific neuroplastic mechanisms are at play.
We also evaluated the sensory-evoked activity of LC neurons 
by applying a noxious stimulation to the paw. As expected and 
in agreement with previous studies, contralateral LC neurons 
are strongly activated by noxious stimulation of the hind paw 
in control and MA animals, consistent with the activation of the 
contralateral ascending pain pathway (Millan, 1999). However, 
an enhanced evoked discharge rate was seen in prolonged MA 
(MA4W), while this discharge was significantly weaker earlier 
in MA (MA1W). This might indicate a dampening in the trans-
mission of ascending information during the early phase of MA 
due to the activity of inhibitory descending circuits, whereas the 
late-phase response to nociceptive inputs is exaggerated, per-
haps due to the disruption of the same inhibitory circuits. The 
increased ratio of evoked/tonic activity in MA4W might result 
in hyperarousal towards the noxious stimulation, a phenom-
enon that has been related to stress-related disorders like anxi-
ety (George et  al., 2013). An analogous increase in the evoked 
response and in TH expression was observed in chronic neuro-
pathic rats under social stress (Bravo et al., 2013) as well as in 
a rat model of posttraumatic stress (George et al., 2013). Hence, 
prolonged MA may produce similar changes in the LC as those 
observed in stressful conditions. Thus, the increased respon-
siveness in prolonged MA might reflect the enhanced pain 
transmission following noxious events as well as repercussions 
on signaling to the corticolimbic areas.
LC activation releases moderate amounts of noradrenaline 
to coordinate arousal, attention, and vigilance (Berridge and 
Foote, 1991; Berridge and Abercrombie, 1999). However, hyper-
activation of LC circuits may lead to excessive noradrenaline 
release, an effect that could provoke anxiogenic-like behavior 
(Berridge and Waterhouse, 2003). Interestingly, PC of the healthy 
paw (contralateral) evoked an LC response that was associated 
with prolonged painful states in spine or brain areas and that 
might fully or partially reflect disturbances to the ascending 
sensory pathways. Nevertheless, as the contralateral paw was 
stimulated after several stimulations of the injured paw, this 
effect may be secondary to the stimulation of the injured paw.
Consistent with our previous studies (Borges et  al., 2014), 
we also detected here an enhancement of pERK1/2 in MA4W 
by immunohistochemistry. We also explored the effect of the 
pharmacological blockade of ERK1/2 phosphorylation (SL327, 
MEK inhibitor) on contralateral LC activity, which reverted the 
alterations to sensory-evoked parameters and postcompression 
activity after prolonged inflammation. Importantly, this effect 
only occurred in pathological conditions and SL327 did not pro-
duce any significant change in the control rats. We also assessed 
whether SL327 administration to the contralateral LC had a 
repercussion on the manifestation of anxiety and pain in MA4W 
rats. Interestingly, while anxiety behavior reverted to control lev-
els following SL327 administration, mechanical hypersensitivity 
remained unaffected. A similar effect was observed in a model 
of visceral pain (acetic acid-induced pain) after subcutaneous 
injection of SL327, where anxiety-like behavior was attenuated 
but the nocifensive responses remained unchanged (Zhong 
et al., 2012). However, in the present study, the lack of effect of 
this compound on pain hypersensitivity after blocking the phos-
phorylation of ERK1/2 may be due to the LC side to which SL327 
is administered (contralateral to the inflamed joint). The spinal 
projections of the LC are thought to be bilateral in the rat strain 
studied here (Herbert and Proudfit, 2002). Therefore, while we 
did not exclude the possibility of observing an effect on pain 
hypersensitivity produced by contralateral injection of the MEK 
inhibitor, this was not the result obtained. The injection of his-
tamine contralateral to nerve injury has been shown to decrease 
mechanical hypersensitivity (Wei et  al., 2014), although this 
effect was less potent than its ipsilateral injection. Since these 
experiments were performed in a time window of 2 to 3 weeks, 
one could argue that persistent pain would lead to the total loss 
of nociceptive intervention on the contralateral side. This could 
explain why the MEK1/2 inhibitor had no effect on pain hyper-
sensitivity on the contralateral side. Another possible explana-
tion is that exacerbated ERK1/2 phosphorylation in the LC is 
not pain related. This is corroborated by the fact that pERK1/2 
expression in the LC peaks a few hours after injection in the CFA 
model (Imbe et al., 2009) and then again after 4 weeks (Borges 
et al., 2014), while pain hypersensitivity persists throughout this 
period. Thus, further studies involving the ipsilateral adminis-
tration of the MEK inhibitor will help to clarify the role of the 
ERK pathway in the control of pain hypersensitivity.
CRF is a well-known anxiety-related neuropeptide that mod-
ulates LC activity (Weiss et al., 1994), and it is a key compound 
in initiating responses to stress in the body. We recently showed 
that microinjection of a CRF antagonist into the contralateral LC 
reverted anxiogenic-like behavior and the pERK1/2 levels in the 
LC, without modifying the withdrawal threshold (Borges et al., 
2015). This suggests that enhanced ERK1/2 phosphorylation may 
be linked to CRF signaling in the contralateral LC after prolonged 
MA and that it is related to the emergence of “affective-behav-
iors.” This also accounts for the possibility that a stress compo-
nent participates in MA, as indicated above.
These data also demonstrate that pain-related anxiety is dis-
sociated from the perception of the sensory component of pain, 
at least in the contralateral/ascending pathway of the LC. This 
result sheds light on the link between pain hypersensitivity and 
the secondary mental effects. In this sense, it was recently shown 
that gabapentin administration produces analgesia, but it does 
not rescue the impaired attention produced by neuropathic pain 
(Berrocoso, 2014; Suto et al., 2014). Hence, pain-related affective 
and cognitive impairment does not appear to be due to the inher-
ent stress provoked by the painful experience but rather, it may 
be attributed to a permanent alteration to a specific circuit.
Our results suggest that a brain region involved in the pro-
cessing of both pain and affective information (the LC) may be 
disrupted by prolonged arthritis, and that this may lead to an 
alteration in the processing of affective information, thereby 
triggering a secondary effect. In an animal model of inflamma-
tory pain (MA), our data show that rats display a sharp decrease 
in their sensorial threshold within 1 week of induction, although 
anxiety-like behavior does not appear until much later (4 weeks). 
This later phase temporally coincides with a decrease in tonic 
LC activity but also with an exacerbated evoked LC response to 
noxious stimulation of the inflamed paw. These changes were 
accompanied by enhanced TH and pERK1/2 expression in the LC. 
Moreover, when ERK1/2 activation was blocked pharmacologi-
cally in the contralateral LC, the exaggerated electrophysiologi-
cal evoked LC response of MA rats was impaired. Importantly, 
ERK1/2 blockade did not modify pain hypersensitivity but rather, 
it reversed the anxiogenic-like behavior. Therefore, we provide 
direct evidence of how restoring ERK1/2 activation in the con-
tralateral LC provides relief from pain-related anxiety without 
affecting nociception.
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Supplementary Material
Supplementary data are available at International Journal of 
Neuropsychopharmacology online.
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